SecBot SecBot
6-K ·Filed Sep 14, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 3/10
Horizonmonths Processed2mo ago SEC0001171843-26-006028
Notable filing: 6-K
Actionable Insight • Neutral

This is a preclinical announcement with no near-term revenue or partnership catalyst. Monitor the November 2026 PEGS Europe data presentation for potential proof-of-concept validation. The company remains a clinical-stage entity with no approved products or disclosed revenue, so the stock will likely trade on pipeline milestones and financing needs.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.07
T+0 close · Sep 14, 2026 · via day close
Latest settled
−2.28%
T+20 · $3.00 · next T+60 in 21d
Vs SPY
−4.54%
α at T+20
Latest observation
−6.32%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $3.07entry
  2. T+1 · 2mo ago −0.98%α −0.52% · $3.04
  3. T+5 · 8w ago +4.56%α +4.45% · $3.21
  4. T+20 · 5w ago −2.28%α −4.54% · $3.00
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts (tolerogenic vaccine and autoantibody binder). Initial experimental data is expected at PEGS Europe in November 2026. This is a preclinical pipeline expansion with no financial data or near-term catalyst, representing a modest strategic update for a clinical-stage company.

Key Facts

  • Evaxion is applying its AI-Immunology platform to autoimmune diseases, expanding beyond cancer and infectious diseases.
  • Two novel concepts are being tested: a tolerogenic vaccine and an autoantibody binder.
  • Initial experimental data will be presented at PEGS Europe in Lisbon on November 18, 2026.
  • No financial terms, partnership agreements, or clinical trial data were disclosed in the filing.

Financial Impact

No financial impact disclosed; preclinical platform expansion with no revenue or cost figures provided.

Risk Factors

  • Preclinical platform expansion carries high technical risk; no guarantee of successful development or partnership.
  • Evaxion's need for additional capital is explicitly noted in forward-looking statements, posing dilution risk.
  • No financial data or guidance was provided, limiting the ability to assess fundamental value.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-006028
Document: f6k_091426.htm0001171843-26-006028
Document: 0001171843-26-006028-index-headers.html0001171843-26-006028
Document: 0001171843-26-006028-index.html0001171843-26-006028
Document: 0001171843-26-006028.txt0001171843-26-006028

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026